What's in Asociación para Evitar la Ceguera en México's pipeline?

Asociación para Evitar la Ceguera en México has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Asociación para Evitar la Ceguera en México's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/asociaci-n-para-evitar-la-ceguera-en-m-xico.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Asociación para Evitar la Ceguera en México — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Asociación para Evitar la Ceguera en México pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
bevacizumab and triamcinolone	bevacizumab and triamcinolone	marketed
bevacizumab intravitreal injection	bevacizumab intravitreal injection	marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Asociación para Evitar la Ceguera en México:

Cite this brief

Drug Landscape (2026). Asociación para Evitar la Ceguera en México — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asociaci-n-para-evitar-la-ceguera-en-m-xico. Accessed 2026-05-17.